Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy

Antiviral Therapy

Volumn 7, Issue 3, 2002, Pages 165-174

  Kempf, Dale J ^a   Isaacson, Jeffrey D ^a   King, Martin S ^a   Brun, Scott C ^a   Sylte, Jacquelyn ^a   Richards, Bruce ^a   Bernstein, Barry ^a   Rode, Richard ^a   Sun, Eugene ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; GENE MUTATION; GENETIC RESISTANCE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENES, VIRAL; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; LOGISTIC MODELS; MUTATION; PHENOTYPE; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 0036768328     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M & Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Journal of Infectious Diseases 1999; 179:1375-1381.
2. Harrigan PR, Hertogs K, Verbiest W, Pauwels R, Larder B, Kemp S, Bloor S, Yip B, Hogg R, Alexander C & Montaner JS. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13:1863-1871.
3. Piketty C, Race E, Castiel P, Belec L, Pevtavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F & Kazatchkine MD. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 13:F71-F77.
4. Para MF, Glidden DV, Coombs RW, Collier AC, Condra JH, Craig C, Bassett R, Leavitt R, Snyder S, McAuliffe V & Boucher C. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS Clinical Trials Group protocol 333. Journal of Infectious Diseases 2000; 182:733-743.
5. Miller V, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, Bloor S, Klauke S, Rabenau H, Phillips A & Staszewski S. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antiviral Therapy 2000; 5:49-55.
6. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L & Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5:41-48.
7. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC & Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Annals of Internal Medicine 1999; 131:813-821.
8. Condra J, Holder JJ, Schleif WA, Bakshi K, Danovich RM, Graham DJ, Shivaprakash M, Holmes K, Saah AJ, Leavitt RY, Chodakewitz JA & Emini EA. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure. Antiviral Therapy 1999; 4:44.
9. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JPA & Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14:F83-F93.
10. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CAB & Dellamonica P. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up. Antiviral Therapy 2000; 5:65-70.
11. Cohen C, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart A & Graham N. Phenotypic resistance testing significantly improves response to therapy: a randomized trial (VIRA 3001). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 Jan-2 Feb 2000, Abstract 237.
12. Murphy RL, Brun S, Hicks C, Eron JT, Gulick R, King M, White AC, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A & Sun E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-F9.
13. Benson CA, Deeks S, Brun SC, Gulick R, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax P, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour A & Sun E. 48 Week safety and antiviral activity of lopinavir/ritonavir plus nevirapine and two nucleoside analogs in human immunodeficiency virus protease inhibitor-experienced patients. Journal of Infectious Diseases 2002; 185:599-607.
14. Molla A, Vasavanonda S, Kumar G, Sham HL, Johnson M, Grabowski B, Denissen JF, Kohlbrenner W, Plattner JJ, Leonard JM, Norbeck DW & Kempf DJ. Human serum attenuates the activity of protease inhibitors toward wildtype and mutant human immunodeficiency virus. Virology 1998; 250:255-262.
15. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E & Rode RA. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. Journal of Virology 2001; 75:7462-7469.
16. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ & Whitcomb JM. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 2000; 44:920-928.
17. Mantel N. Assessing laboratory evidence for neoplastic activity. Biometrics 1980; 36:381-399.
18. Tukey JW, Ciminera JL & Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 1985; 41:295-301.
19. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel. Journal of the American Medical Association 2000; 283:2417-2426.
20. Bertz R, Lam W, Hsu A, Granneman GR & Sun E. Effects of gender, race, age and weight on the pharmacokinetics of lopinavir after single-dose Kaletra. 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, the Netherlands, 2-4 April 2001, Abstract 3,11.
21. Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC & Fletcher CV. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrobial Agents and Chemotherapy 2001; 45:236-242.
22. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM & Dellamonica P. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 1333; 14:1333-1339.
23. Kempf D, Hsu A, Jiang P, Rode R, Hertogs K, Larder B, Zolopa A, Shulman N, Havlir D, Gallant J, Race E, Boller S, Swerdlow J, Jasinsky O, Renz C & Sun E. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients is highly correlated with virtual inhibitory quotient. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, 4-8 February, 2001, Abstract 523.
24. Larder BA, Hertogs K, Bloor S, van den Eynde C, DeCian W, Wang YY, Freimuth WW & Tarpley G. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14:1943-1948.
25. Parkin NT, Chappey C, Maranta M, Whitehurst N & Petropoulos CJ. Genotypic and phenotypic analysis of a large database of patient samples reveals distinct patterns of protease inhibitor cross-resistance. Antiviral Therapy 2001; 6:49.
26. Ruane P, Mendonca J, Timerman A, Cernohous P, Bauer E, Bernstein B & Sun E. Kaletra vs. nelfinavir in antiretroviral-naive subjects: week 60 comparison in a phase III, blinded, randomized clinical trial. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8-11 July 2001, Abstract 6.
27. Kempf D, Bernstein B, King M, Cernohous P, Moseley J, Gu K, Bauer E & Sun E. Comparison of the emergence of genotypic resistance over 60 weeks of therapy with lopinavir/ritonavir (Kaletra) or nelfinavir plus d4T/3TC. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8-11 July 2001, Abstract 129.